Covid-19: BioNTech, Pfizer say 3 vaccine doses neutralise Omicron variant
If required, both firms claimed they can provide an Omicron-based vaccination in March 2022
BioNTech as well as Pfizer claimed on Wednesday a three-shot program of their Covid-19 vaccination was revealed to create a neutralising result versus the brand-new Omicron version in a research laboratory examination.
In the initial main declaration from vaccination suppliers on the most likely effectiveness of their fired versus Omicron, BioNTech as well as Pfizer claimed in a joint declaration that 2 vaccination dosages led to dramatically reduced neutralising antibodies yet that a 3rd dosage of their vaccination raised the neutralising antibodies by an element of 25.
They included that, if required, they can provide an Omicron-based vaccination in March 2022.